India, April 7 -- MAK Capital is urging Evotec SE to take its U.S. subsidiary, Just Biologics, public and to accelerate its cost-cutting measures. They believe more decisive steps are necessary since Evotec's stock has plummeted about 85% over the past five years.
In a letter sent out earlier this month, MAK Capital argued that a U.S. listing for Just Biologics could place the company's value over 1 billion euros.
This move could also open up investment opportunities, generate new capital for growth, and help retain top talent. This year alone, Evotec's shares have dropped around 18%, leaving the company valued at about 796 million euros.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Evotec has sta...